Stay updated with breaking news from Dose Selection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study results/Study Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat
/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, "Eisai") announced today that the company will present research from its Alzheimer's...
/PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid...
STOCKHOLM, July 26, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present new data for lecanemab (BAN2401), an investigational anti-amyloid beta (Aß)
.jpg){kind=logo}
Humanized mice provide tools for the preclinical development of drugs recognizing human-specific targets